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VGiven the well-accepted limitations of coronary angiogra-
phy, investigators and clinicians have had a strong interest
in developing new approaches to defining the luminal
encroachment, composition, and functional consequences of
coronary atheromas. Intracoronary imaging techniques such
as intravascular ultrasound (IVUS) were the initial tech-
niques applied for this purpose (1). The validation of
fractional flow reserve (FFR) as a measure of the functional
significance of intermediate coronary stenoses has also
provided an important advance in our ability to determine
appropriate application of percutaneous coronary interven-
tion (PCI) (2). More recently, advanced imaging techniques,
such as virtual histology-intravascular ultrasound (VH-IVUS) to
See pages 1058, 1073, and 1080
define high-risk plaques and necrotic cores by their ultra-
sound characteristics, and near infrared spectroscopy
(NIRS) to detect lipid-rich plaques by their cholesterol ester
composition, have also been developed. Despite these ad-
vances, limitations have continued in the evaluation of
coronary atherosclerosis, and techniques such as angioscopy,
palpography, shear stress imaging, and Raman and fluores-
cence spectroscopy are being actively studied (3). With its
recent commercialization, optical coherence tomography
(OCT) holds the potential to make significant contributions
to this field.
Although the initial application of OCT to blood vessels
by the Fujimoto group occurred in the mid-1990s (4), it has
taken a number of years of development and validation to
bring it to clinical use (3). OCT employs infrared light
(invisible to the naked eye) to produce tomographic images,
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intravascular imaging techniques. OCT is analogous to
ultrasound B-mode imaging, but measures the intensity of
reflected or backscattered light rather than acoustic waves.
Light from the OCT is split, with a portion sent to the
patient’s artery and a portion to a reference arm, generating
a reflected interference pattern that is analyzed for backscat-
ter as a function of delay time to determine depth and
transverse position. The intensity of the reflected light,
which is dependent on the differences in refractive indices
(backscatter and absorption) of the imaged tissue, is then
displayed as an orange-red or grayscale image. Because
plaque components have different intrinsic refractive indices
(i.e., lipids have high attenuation and thus low penetration
depth and cannot be seen as well, whereas calcium and
collagen have low attenuation and high penetration depth),
distinct patterns of composition can be generated. The
penetration depth of infrared light wavelengths (1.3 m)
sed in coronary OCT is approximately 0.1 to 2.0 mm.
ecause OCT is attenuated by blood before it reaches the
essel wall, the field of view must be flushed clear during
maging.
OCT imaging was initially performed using a time-
omain algorithm that was limited by slow imaging speeds.
his necessitated proximal balloon occlusion and flushing,
eading to potential ischemia. The current OCT systems use
frequency-domain protocol that has rapid imaging speeds
20 mm/s) performed in conjunction with an optically
ransparent flush not requiring balloon occlusion. This
mportant advance will allow widespread clinical application
nd reduced potential for complications (5).
A key question at this point is what information can be
btained from OCT that is not available with current
echniques. For example, IVUS provides full vessel anatom-
cal architecture; quantitates luminal compromise, extent of
theroma burden, inward or outward remodeling, stent
imensions, and malapposition; and has been validated in
ultiple clinical trials (1). However, IVUS has limitations
n spatial resolution and plaque/thrombus characterization.
H-IVUS has been developed to further characterize ath-
roma components into calcified plaque, necrotic core,
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ing Regional Observations to Study Predictors of Events in
the Coronary Tree) trial (6) demonstrated that IVUS-
derived measures of plaque burden and VH-IVUS determi-
nation of thin-cap fibroatheromas (TCFA) were additive in
predicting future cardiovascular events. Prospective clinical
data with NIRS are not yet available, and comparisons of
TCFA derived by VH-IVUS and necrotic cores detected by
NIRS evaluation of cholesterol content would be of interest
to assess whether these measures are complementary or
redundant.
It is clear at this point that OCT provides high-
resolution, well-defined images of intraluminal and endo-
thelial/intimal structures such as ruptured plaques, thrombi,
spontaneous dissections, and angiographically vague coro-
nary anatomy, such as ostial, bifurcation, and left main
lesions. It also is able to detect fibrous cap thickness and to
identify TCFAs (75 m), a key component of rupture-
prone lesions. OCT is of value in determining stent param-
eters (edge dissections, expansion, apposition, neointima,
stent coverage, and defining mechanisms of stent resteno-
sis). Therefore, it will likely have a significant role, and
perhaps become a preferred modality compared with IVUS,
in facilitating the performance of PCI. However, due to its
limited penetration and high attenuation by some plaque
components, it remains to be seen whether it will ultimately
discriminate lipid versus nonlipid components such as the
necrotic cores that are associated with high potential for
plaque rupture. It also cannot fully measure plaque burden,
particularly in larger arteries, or adequately assess remodel-
ing due to depth of penetration issues, and may not be as
amenable to testing pharmacological therapeutic interven-
tions as IVUS.
In this issue of the Journal, four reports provide initial
insights into addressing the clinical potential of OCT. In
the first study by Tearney et al. (7), a group of approximately
250 interested investigators and industry representatives
developed a consensus report on proposed definitions,
applications, and standards for the clinical use of OCT. The
document, from a group of early developers and interested
practitioners of the technique, defines their view of the state
of the art. They provide a detailed overview of most aspects
of OCT, including documentation of the level of evidence
currently available supporting clinical applications. Al-
though this group is not sanctioned under the aegis of any
official organization, it will likely serve as the beginning of a
broad discussion and roadmap for performing, analyzing, and
reporting future studies related to OCT.However, several gaps
of knowledge remain: 1) most of the data come from small
studies and largely descriptive datasets; 2) limitations in imag-
ing the vessel wall related to the procedure and generation of
imaging artifacts will likely become more apparent as more
experience is obtained; 3) the OCT evidence base on plaque
composition will need to be supported by future studies; and
4) committees with broader interests should ultimately provideguidelines to define the usefulness of the individual imaging
technologies as the evidence base increases.
The three other reports in this issue show the potential
clinical utility of OCT. Alfonso et al. (8) demonstrate that
OCT may detect angiographically occult spontaneous cor-
onary dissections in patients that have nonatherosclerotic
cardiovascular disease and that this knowledge changes
clinical care. Gonzalo et al. (9) performed a comparison of
OCT and FFR in intermediate lesions and showed that
although OCT-derived measures of plaque of minimal
lumen diameter appeared to be slightly better than FFR in
defining functional significance, the difference was quite
small and did not appear to be clinically significant due to
low specificity. Finally, Kostis and Jang (10) demonstrated
that acute in-lab stent thrombosis could be clearly observed
to resolve by OCT within 24 h in response to antiplatelet
therapy.
When viewing OCT images, one is struck by the exqui-
site detail and resolution of the technique, particularly in
defining endothelial or vessel lumen/near field–based struc-
tures. However, although such previously unseen beautiful
images of the coronary vasculature are nice to look at, the
usefulness of this technique will ultimately rest on its ability
to accurately identify the structures visualized. Importantly,
the images must also result in improved clinical outcomes;
for example, they should enhance stent deployment, predic-
tion of late stent outcomes, and overall success of PCI.
However, predicting future cardiovascular events in native
lesions is a daunting task and perhaps a bit too much to ask
for a stand-alone anatomically based technique. Advances in
complementary imaging techniques, such as molecular im-
aging of pro-inflammatory components including macro-
phages and their byproducts and of oxidized lipids, which
make up a large component of the necrotic core (11), may
ultimately provide a more comprehensive assessment of risk.
They may also guide targeting of focal and systemic thera-
pies if further validated in clinical studies (12). For example,
targeting oxidation-specific epitopes in high-risk lesions can
be seen as an example of a “biotheranostic” approach;
monoclonal antibodies can detect OSE in plasma using in
vitro assays. When OSE biomarkers and other biomarkers
are elevated, antibody-based magnetic resonance nanopar-
ticles may be used to image them in the vessel wall. Finally,
when detected at specific vascular sites, these oxidation-
specific epitopes may be treated with a larger dose of the
same antibody. This biotheranostic paradigm has been
developed in our laboratory over the last 10 years using
murine and human oxidation-specific antibodies (13–15).
To define the ultimate clinical utility of OCT, standards
will need to be defined prospectively and linked to outcomes
with appropriate studies. Undoubtedly, OCT will have an
important niche in specific clinical situations where current
imaging techniques have limitations. As we go forward,
defining the optimal utility of OCT will provide a fertile
and exciting opportunity for clinical investigation.
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